Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
Portfolio Pulse from
A study published in the Journal of American Society of Nephrology highlights the efficacy and safety of sotagliflozin for people with Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD). The study found that sotagliflozin, when used with insulin, had similar effects on lowering glycated hemoglobin (HbA1c) in T1D patients with CKD as in those without CKD.
November 05, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals' sotagliflozin shows promising results in reducing HbA1c in T1D patients with CKD, similar to those without CKD, according to a new study.
The study's positive results on sotagliflozin's efficacy and safety in T1D patients with CKD could boost investor confidence in Lexicon Pharmaceuticals, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80